Compare Stocks → 1970’s computer coder Issues Shocking AI Warning (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVTENASDAQ:EVLONASDAQ:PRQRNASDAQ:RAINNASDAQ:SPPI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$21.24+1.0%$24.61$9.41▼$32.42$592.60M1.4129,753 shs73,498 shsEVLOEvelo Biosciences$0.04$0.05$0.03▼$13.93$835K1.9439,067 shs665 shsPRQRProQR Therapeutics$1.99-0.5%$2.13$1.11▼$3.29$161.91M0.3259,618 shs53,969 shsRAINRain Oncology$1.21$1.21$0.82▼$11.32$44.02M0.27550,818 shsN/ASPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/A5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics+2.94%+0.96%-20.54%+2.48%-3.62%EVLOEvelo Biosciences-7.17%-7.37%+5.01%-12.80%-98.24%PRQRProQR Therapeutics+0.50%0.00%-6.10%-4.76%-5.66%RAINRain Oncology0.00%0.00%0.00%0.00%-86.78%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%-14.17%Gold Set to EXPLODE! (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTEAerovate Therapeutics1.0928 of 5 stars3.51.00.00.01.71.70.0EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/APRQRProQR Therapeutics2.5486 of 5 stars3.55.00.00.03.70.00.0RAINRain OncologyN/AN/AN/AN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics3.00Buy$49.33132.27% UpsideEVLOEvelo Biosciences2.00HoldN/AN/APRQRProQR Therapeutics3.00Buy$3.6080.90% UpsideRAINRain Oncology2.00HoldN/AN/ASPPISpectrum Pharmaceuticals2.00HoldN/AN/ACurrent Analyst RatingsLatest RAIN, EVLO, AVTE, SPPI, and PRQR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024PRQRProQR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.80 ➝ $2.004/4/2024AVTEAerovate TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/1/2024AVTEAerovate TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$35.003/25/2024AVTEAerovate TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$21.00 ➝ $65.003/14/2024PRQRProQR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.00 ➝ $2.503/14/2024PRQRProQR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 5/9/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AEVLOEvelo BiosciencesN/AN/AN/AN/A($0.92) per shareN/APRQRProQR Therapeutics$7.05M22.97N/AN/A$0.55 per share3.62RAINRain OncologyN/AN/AN/AN/A$3.11 per shareN/ASPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$2.88N/AN/AN/AN/A-61.62%-55.08%5/20/2024 (Estimated)EVLOEvelo Biosciences-$114.53M-$13.29N/A∞N/AN/AN/A-189.58%5/13/2024 (Estimated)PRQRProQR Therapeutics-$30.43M-$0.39N/AN/AN/A-431.65%-56.71%-19.15%5/21/2024 (Estimated)RAINRain Oncology-$75.72M-$2.06N/AN/AN/AN/A-82.96%-68.31%N/ASPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/ALatest RAIN, EVLO, AVTE, SPPI, and PRQR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/25/2024Q4 2023AVTEAerovate Therapeutics-$0.68-$0.74-$0.06-$0.74N/AN/A3/13/2024Q4 2023PRQRProQR Therapeutics-$0.08-$0.08N/A-$0.08$27.88 million$3.54 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ARAINRain OncologyN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A7.047.04EVLOEvelo BiosciencesN/A0.480.48PRQRProQR Therapeutics0.103.543.54RAINRain OncologyN/A5.585.58SPPISpectrum PharmaceuticalsN/A2.712.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/AEVLOEvelo Biosciences0.31%PRQRProQR Therapeutics32.65%RAINRain Oncology65.84%SPPISpectrum Pharmaceuticals21.67%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics19.30%EVLOEvelo Biosciences1.02%PRQRProQR Therapeutics8.40%RAINRain Oncology17.40%SPPISpectrum Pharmaceuticals2.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics5127.90 million22.52 millionOptionableEVLOEvelo Biosciences6618.98 million18.79 millionNo DataPRQRProQR Therapeutics15681.36 million74.52 millionOptionableRAINRain Oncology6336.38 million30.05 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableRAIN, EVLO, AVTE, SPPI, and PRQR HeadlinesSourceHeadlinePneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024globenewswire.com - May 2 at 7:00 AMSpectrum Pharmaceuticals gets grant for crystalline form of quinazoline compound and hydrochloride saltspharmaceutical-technology.com - April 24 at 10:28 AMAssertio Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - ASRTmarkets.businessinsider.com - February 21 at 11:54 PMLevi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming Deadlinemarkets.businessinsider.com - February 21 at 1:34 PMLost Money on Assertio Holdings, Inc.(ASRT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinskymarkets.businessinsider.com - February 8 at 2:32 PMAssertio Holdings, Inc. (NASDAQ: ASRT) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Actionmarkets.businessinsider.com - February 5 at 2:12 PMGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Assertio Holdings, Inc. (ASRT)stockhouse.com - February 1 at 1:26 PMCLASS ACTION NOTICE: Berger Montague Encourages Assertio Holdings, Inc. (ASRT) Investors to Inquire About a Securities Fraud Class Actionmarkets.businessinsider.com - February 1 at 1:16 AMSHAREHOLDER ALERT: Levi & Korsinsky Notifies Assertio Holdings, Inc.(ASRT) Investors of a Class Action Lawsuit and Upcoming Deadlinestockhouse.com - January 30 at 10:18 AMINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Assertio Holdings, Inc. (ASRT) Investorstmcnet.com - January 26 at 6:41 PMLobbying revenues continued climbing amid stalled Hill actionpolitico.com - January 23 at 7:48 PMINVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming Deadlinestockhouse.com - January 13 at 10:52 PMEye Melanoma Market Size Worth USD 9.56 Billion in 2032 | Emergen Researchfinance.yahoo.com - January 12 at 6:07 AMVaccine Adjuvant Market Size Worth USD 1.75 Billion in 2032 | Emergen Researchfinance.yahoo.com - January 10 at 10:13 AMSHAREHOLDER ALERT: Potential Recovery for Assertio Holdings, Inc. (ASRT) Investorsmsn.com - January 9 at 8:33 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Assertio Holdings, Inc. - ASRTmarkets.businessinsider.com - November 9 at 7:46 PM$19.30+ Bn Neutropenia Treatment Market to Grow at 5.4% CAGR, Globally, by 2027pharmiweb.com - November 8 at 7:16 PMDisney offers streaming service discount amid Spectrum blackoutctpost.com - September 8 at 6:23 PMAnalyzing Spectrum Pharmaceuticals Inc. (SPPI) After Recent Trading Activityknoxdaily.com - July 31 at 5:06 PMSpectrum Pharmaceuticals Inc. [SPPI] CFO makes an insider sale of 32,387 shares worth 35,496.knoxdaily.com - July 28 at 10:55 AMBuy Spectrum Pharmaceuticals For Exposure To Assertio Holdingsseekingalpha.com - July 24 at 6:02 AMPotential Price Increase for Spectrum Pharmaceuticals Inc. (SPPI) After Recent Insider Activityknoxdaily.com - July 19 at 7:14 PMNegative sentiment towards SPPI reflected by a jump of 6.23% in short interestknoxdaily.com - July 14 at 9:14 PMSpectrum Pharmaceuticals Inc. [SPPI] Investment Appeal on the Riseknoxdaily.com - July 11 at 7:15 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsSeagate Technology Warns Cloud Demand is Heating Up April 30, 2024 10:10 AMView Seagate Technology Warns Cloud Demand is Heating Up Planet Labs Soars Fueled by AI Data Demand April 18, 2024 7:00 AMView Planet Labs Soars Fueled by AI Data Demand All Headlines Company DescriptionsAerovate TherapeuticsNASDAQ:AVTEAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Evelo BiosciencesNASDAQ:EVLOEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.ProQR TherapeuticsNASDAQ:PRQRProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Rain OncologyNASDAQ:RAINAs of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.Spectrum PharmaceuticalsNASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.